New hope for kids with rare cancers: drug targets tumor growth

NCT ID NCT02867592

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 28, 2026 · Updated 5 times

Summary

This phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study aims to see if the drug can shrink tumors or control the disease in 109 participants aged up to 30 years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Cabozantinib (a drug that blocks multiple enzymes involved in tumor growth and blood vessel formation)
What this could lead to: If successful, this could provide a new treatment option for children and young adults with rare cancers that have not responded to standard therapies.
What could go wrong: This is a phase 2 trial with a relatively small number of participants (109). The drug may not work for all cancer types, and side effects can be significant. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

109 people

The number who actually took part.

Started

May 2017

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 30 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Upper age limit of =\< 18 years of age for medullary thyroid carcinoma (MTC), renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) =\< 30 years for all other diagnoses * Patients must have a body surface area \>= 0.35 m\^2 * Patients must have recurrent or refractory disease, or newly diagnosed disease with no known curative therapy or therapy proven to prolong survival with an acceptable quality of life; patients must have had histologic verification of one of the malignancies listed below at original diagnosis or at relapse: * Ewing sarcoma * Rhabdomyosarcoma (RMS) * Non-rhabdomyosarcoma soft tissue sarcomas (STS) including microphthalmia transcription factor associated STS (alveolar soft part sarcoma \[ASPS\] and clear cell sarcoma \[CCS\]) * Osteosarcoma * Wilms tumor * Rare tumors * Medullary thyroid carcinoma (MTC) * Renal cell carcinoma (RCC) * Hepatocellular carcinoma (HCC) * Hepatoblastoma * Adrenal coertex carcinoma * Pediatric solid tumors (including central nervous system \[CNS\] tumors) with known molecular alterations in the targets of XL184 (i.e., MET amplification, overexpression, activating mutation, MET translocation, MET exon skipping mutations, activating RET mutations, RET rearrangement, overexpression or activation of AXL); documentation of the alteration from a Clinical Laboratory Improvement Act (CLIA) certified laboratory will be required * Note: Documentation of any known tumor molecular alterations and RET mutation status for patients with MTC (germline) must be uploaded via the RAVE system * Patients must have radiographically measurable disease; measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm) * Note: The following do NOT qualify as measurable disease: * Malignant fluid collections (e.g., ascites, pleural effusions) * Bone marrow infiltration * Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography \[PET\] scans) * Elevated tumor markers in plasma or cerebrospinal fluid (CSF) * Previously radiated lesions that have not demonstrated clear progression post radiation * Leptomeningeal lesions that do not meet the measurement parameters noted above * Patients must have a Lansky or Karnofsky performance status score of \>= 50, corresponding to Eastern Cooperative Oncology Group (ECOG) categories 0, 1 or 2; use Karnofsky for patients \> 16 years of age and Lansky for patients =\< 16 years of age; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study * Patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea) * At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed after receiving pegfilgrastim * Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count \[ANC\] counts): \>= 7 days after the last dose of agent * Antibodies: \>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =\< 1 * \>= 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small port); \>= 6 weeks must have elapsed since treatment with therapeutic doses of M-Iodobenzylguanidine (MIBG); \>= 3 months must have elapsed if prior craniospinal XRT was received, if \>= 50% of the pelvis was irradiated, or if total-body irradiation (TBI) was received; \>= 6 weeks must have elapsed if other substantial bone marrow irradiation was given * Subjects should not have any clinically relevant ongoing complications from prior radiation therapy (i.e., radiation esophagitis or other inflammation of the viscera) * No evidence of active graft versus (vs.) host disease and \>= 2 months must have elapsed since transplant * Not previously received XL184 or another MET/HGF inhibitor (tivantinib or crizotinib); there are no limits on number of prior therapeutic regimens; patients who have been treated with prior VEGF pathway, or RET inhibitors (except XL184) may be eligible * Peripheral absolute neutrophil count (ANC) \>= 1000/uL for patients with solid tumors without bone marrow involvement * Platelet count \>= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment) for patients with solid tumors without bone marrow involvement * Hemoglobin \>= 8.0 g/dL (may receive red blood cell \[RBC\] transfusions) for patients with solid tumors without bone marrow involvement * Peripheral absolute neutrophil count (ANC) \>= 750/uL for patients with solid tumors and known bone marrow metastatic disease * Platelet count \>= 50,000/uL for patients with solid tumors and known bone marrow metastatic disease * Hemoglobin \>= 8.0 g/dL for patients with solid tumors and known bone marrow metastatic disease * Transfusions are permitted to meet both the platelet and hemoglobin criteria for patients with known bone marrow metastatic disease; patients must not be known to be refractory to red blood cell or platelet transfusions * Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 or a serum creatinine based on age/gender as follows: * 2 to \< 6 years of age * Male and female: 0.8 (maximum serum creatinine \[mg/dL\]) * 6 to \< 10 years of age * Male and female: 1 (maximum serum creatinine \[mg/dL\]) * 10 to \< 13 years of age * Male and female: 1.2 (maximum serum creatinine \[mg/dL\]) * 13 to \< 16 years of age * Male 1.5 (maximum serum creatinine \[mg/dL\]) * Female: 1.4 (maximum serum creatinine \[mg/dL\]) * \>= 16 years of age * Male: 1.7 (maximum serum creatinine \[mg/dL\]) * Female: 1.4 (maximum serum creatinine \[mg/dL\]) * Urine protein: =\< 30 mg/dl in urinalysis or =\< 1+ on dipstick, unless quantitative protein is \< 1000 mg in a 24 hour (h) urine sample * Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age * Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 135 U/L (3 x ULN) (for the purpose of this study, the ULN for SGPT is 45 U/L) * Serum albumin \>= 2.8 g/dL * No history of congenital prolonged corrected QT (QTc) syndrome, New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) * No clinically significant cardiac arrhythmias, stroke or myocardial infarction within 6 months prior to enrollment * QTc =\< 480 msec; Note: Patients with grade 1 prolonged QTc (450- 480 msec) at the time of study enrollment should have correctable causes of prolonged QTc addressed if possible (i.e., electrolytes, medications) * Patients with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures may be enrolled * CNS toxicity =\< grade 2 with the exception of decreased tendon reflex (DTR); any grade of DTR is eligible * A blood pressure (BP) =\< the 95th percentile for age, height, and gender for pediatric patients \< 18 years old and =\< 140/90 mmHg for patients \>= 18 years old; patients should not be receiving medication for treatment of hypertension (except patients with Wilms tumor and RCC who may be eligible if on stable doses of no more than one anti-hypertensive medication with a baseline BP =\< ULN for pediatric patients and =\< 140/90 for adult patients); please note that 3 serial blood pressures should be obtained and averaged to determine baseline BP * International normalized ratio (INR) =\< 1.5 * Serum amylase =\< 1.5 x ULN * Serum lipase =\< 1.5 x ULN Exclusion Criteria: * Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use two methods of birth control- a medically accepted barrier method of contraceptive method (e.g., male or female condom) and a second effective method of birth control-during protocol therapy and for at least 4 months after the last dose of XL184; abstinence is an acceptable method of birth control * Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment (14 days if pegfilgrastim) * Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid * Previous treatment with XL184 (cabozantinib) or another MET/HGF inhibitor (tivantinib, crizotinib) * Patients who are currently receiving another investigational drug are not eligible * Patients who are currently receiving other anti-cancer agents are not eligible * Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial * Patients must not be receiving any of the following potent CYP3A4 inducers or inhibitors: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's wort * Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin, and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel) are prohibited * Note: Low-dose aspirin for cardioprotection (per local applicable guidelines) and low dose, low molecular weight heparins (LMWH) are permitted; anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no complications from a thromboembolic event or the anticoagulation regimen * Patients must not have received enzyme-inducing anticonvulsants within 14 days prior to enrollment * Patients who are receiving drugs that prolong QTc are not eligible * Patients who are unable to swallow intact tablets are not eligible * Patients who have an uncontrolled infection are not eligible * Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible * Patients with active bleeding are not eligible; specifically, no clinically significant gastrointestinal (GI) bleeding, GI perforation, intra-abdominal abscess or fistula for 6 months prior to enrollment, no hemoptysis or other signs of pulmonary hemorrhage for 3 months prior to enrollment; patients with evidence of an acute intracranial or intratumoral hemorrhage on CT or MRI are not eligible (patients with evidence of resolving hemorrhage will be eligible); in patients with CNS tumors, an MRI with ECHO gradient sequences would be required to exclude presence of petechial hemorrhages * Patients who have had or are planning to have the following invasive procedures are not eligible: * Major surgical procedure, laparoscopic procedure, or open biopsy within 28 days prior to enrollment * Central line placement or subcutaneous port placement is not considered major surgery but must be placed at least 3 days prior to enrollment for external lines (e.g., Hickman or Broviac catheter, peripherally inserted central catheter \[PICC\]) and at least 7 days prior to enrollment for a subcutaneous port * Core biopsy within 7 days prior to enrollment * Fine needle aspirate within 7 days prior to enrollment * Surgical or other wounds must be adequately healed prior to enrollment * NOTE: For purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy * Patients who have had significant traumatic injury within 28 days prior to enrollment are not eligible * Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of the study drug are not eligible

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex carcinoma alveolar soft part sarcoma cancer Carcinoma, Medullary central nervous system cancer central nervous system neoplasm childhood kidney Wilms tumor clear cell sarcoma Ewing sarcoma familial medullary thyroid carcinoma hepatoblastoma hepatocellular carcinoma kidney Wilms tumor medullary thyroid gland carcinoma neoplasm osteosarcoma primary brain neoplasm refractory malignant neoplasm renal cell carcinoma rhabdomyosarcoma sarcoma soft tissue sarcoma Wilms tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adrenal cortical carcinoma Alveolar soft part sarcoma Central nervous system neoplasm Childhood clear cell sarcoma of soft tissue Clear cell sarcoma of soft tissue Ewing sarcoma Hepatoblastoma Hepatocellular carcinoma Osteosarcoma Recurrent adrenal cortical carcinoma Recurrent alveolar soft part sarcoma Recurrent clear cell sarcoma of soft tissue Recurrent Ewing sarcoma Recurrent hepatoblastoma Recurrent hepatocellular carcinoma Recurrent kidney Wilms tumor Recurrent malignant solid neoplasm Recurrent osteosarcoma Recurrent primary malignant central nervous system neoplasm Recurrent renal cell carcinoma Recurrent rhabdomyosarcoma Recurrent soft tissue sarcoma Recurrent thyroid gland medullary carcinoma Refractory adrenal cortical carcinoma Refractory alveolar soft part sarcoma Refractory clear cell sarcoma of soft tissue Refractory Ewing sarcoma Refractory hepatoblastoma Refractory hepatocellular carcinoma Refractory malignant solid neoplasm Refractory osteosarcoma Refractory primary central nervous system neoplasm Refractory primary malignant central nervous system neoplasm Refractory renal cell carcinoma Refractory rhabdomyosarcoma Refractory soft tissue sarcoma Refractory thyroid gland medullary carcinoma Refractory Wilms tumor Renal cell carcinoma Rhabdomyosarcoma Soft tissue sarcoma Solid neoplasm Thyroid gland medullary carcinoma Wilms tumor

Contacts and locations

Locations

AdventHealth Orlando

Orlando, Florida, 32803, United States
Alfred I duPont Hospital for Children

Wilmington, Delaware, 19803, United States
Alliance for Childhood Diseases/Cure 4 the Kids Foundation

Las Vegas, Nevada, 89135, United States
Arkansas Children's Hospital

Little Rock, Arkansas, 72202-3591, United States
Arnold Palmer Hospital for Children

Orlando, Florida, 32806, United States
Ascension Saint Vincent Indianapolis Hospital

Indianapolis, Indiana, 46260, United States
BI-LO Charities Children's Cancer Center

Greenville, South Carolina, 29605, United States
Barnes-Jewish Hospital

St Louis, Missouri, 63110, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center

Houston, Texas, 77030, United States
Blank Children's Hospital

Des Moines, Iowa, 50309, United States
C S Mott Children's Hospital

Ann Arbor, Michigan, 48109, United States
Cardinal Glennon Children's Medical Center

St Louis, Missouri, 63104, United States
Carle Cancer Center

Urbana, Illinois, 61801, United States
Carle Physician Group-Effingham

Effingham, Illinois, 62401, United States
Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938, United States
Carle at The Riverfront

Danville, Illinois, 61832, United States
Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203, United States
Children's Healthcare of Atlanta - Arthur M Blank Hospital

Atlanta, Georgia, 30329, United States
Children's Hospital Colorado

Aurora, Colorado, 80045, United States
Children's Hospital Los Angeles

Los Angeles, California, 90027, United States
Children's Hospital New Orleans

New Orleans, Louisiana, 70118, United States
Children's Hospital and Medical Center of Omaha

Omaha, Nebraska, 68114, United States
Children's Hospital of Alabama

Birmingham, Alabama, 35233, United States
Children's Hospital of Orange County

Orange, California, 92868, United States
Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, 15224, United States
Children's Hospital of San Antonio

San Antonio, Texas, 78207, United States
Children's Hospital of The King's Daughters

Norfolk, Virginia, 23507, United States
Children's Hospital of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Children's Hospitals and Clinics of Minnesota - Minneapolis

Minneapolis, Minnesota, 55404, United States
Children's Mercy Hospitals and Clinics

Kansas City, Missouri, 64108, United States
Children's National Medical Center

Washington D.C., District of Columbia, 20010, United States
Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Comprehensive Cancer Centers of Nevada-Horizon Ridge

Henderson, Nevada, 89052, United States
Connecticut Children's Medical Center

Hartford, Connecticut, 06106, United States
Corewell Health Children's

Royal Oak, Michigan, 48073, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756, United States
Dayton Children's Hospital

Dayton, Ohio, 45404, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
East Carolina University

Greenville, North Carolina, 27834, United States
East Tennessee Childrens Hospital

Knoxville, Tennessee, 37916, United States
Eastern Maine Medical Center

Bangor, Maine, 04401, United States
El Paso Children's Hospital

El Paso, Texas, 79905, United States
Golisano Children's Hospital of Southwest Florida

Fort Myers, Florida, 33908, United States
Gundersen Lutheran Medical Center

La Crosse, Wisconsin, 54601, United States
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Henry Ford Health Saint John Hospital

Detroit, Michigan, 48236, United States
Hope Cancer Care of Nevada-Pahrump

Pahrump, Nevada, 89048, United States
Huron Medical Center PC

Port Huron, Michigan, 48060, United States
Iowa Lutheran Hospital

Des Moines, Iowa, 50316, United States
Iowa Methodist Medical Center

Des Moines, Iowa, 50309, United States
Johns Hopkins All Children's Hospital

St. Petersburg, Florida, 33701, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Kaiser Permanente Downey Medical Center

Downey, California, 90242, United States
Kaiser Permanente Los Angeles Medical Center

Los Angeles, California, 90027, United States
Kaiser Permanente Moanalua Medical Center

Honolulu, Hawaii, 96819, United States
Kaiser Permanente-Anaheim

Anaheim, California, 92806, United States
Kaiser Permanente-Bellflower

Bellflower, California, 90706, United States
Kaiser Permanente-Capitol Hill Medical Center

Washington D.C., District of Columbia, 20002, United States
Kaiser Permanente-Fontana

Fontana, California, 92335, United States
Kaiser Permanente-Oakland

Oakland, California, 94611, United States
Kaiser Permanente-Rio San Diego

San Diego, California, 92108, United States
Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, 96826, United States
Lafayette Family Cancer Center-EMMC

Brewer, Maine, 04412, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016, United States
Loma Linda University Medical Center

Loma Linda, California, 92354, United States
Lucile Packard Children's Hospital Stanford University

Palo Alto, California, 94304, United States
Lurie Children's Hospital-Chicago

Chicago, Illinois, 60611, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States
MedStar Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States
Medical City Dallas Hospital

Dallas, Texas, 75230, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Mercy Hospital Saint Louis

St Louis, Missouri, 63141, United States
MetroHealth Medical Center

Cleveland, Ohio, 44109, United States
Morristown Medical Center

Morristown, New Jersey, 07960, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
NYU Langone Hospital - Long Island

Mineola, New York, 11501, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
Nationwide Children's Hospital

Columbus, Ohio, 43205, United States
Nemours Children's Clinic - Pensacola

Pensacola, Florida, 32504, United States
Nemours Children's Clinic-Jacksonville

Jacksonville, Florida, 32207, United States
Nemours Children's Hospital

Orlando, Florida, 32827, United States
Nicklaus Children's Hospital

Miami, Florida, 33155, United States
Norton Children's Hospital

Louisville, Kentucky, 40202, United States
OSF Children's Hospital of Illinois

Peoria, Illinois, 61637, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
ProMedica Flower Hospital

Sylvania, Ohio, 43560, United States
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital

Toledo, Ohio, 43606, United States
Providence Alaska Medical Center

Anchorage, Alaska, 99508, United States
Providence Sacred Heart Medical Center and Children's Hospital

Spokane, Washington, 99204, United States
Radiation Oncology Associates

Reno, Nevada, 89509, United States
Rady Children's Hospital - San Diego

San Diego, California, 92123, United States
Rainbow Babies and Childrens Hospital

Cleveland, Ohio, 44106, United States
Riley Hospital for Children

Indianapolis, Indiana, 46202, United States
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center

Denver, Colorado, 80218, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital

New Brunswick, New Jersey, 08903, United States
Saint Francis Cancer Center

Greenville, South Carolina, 29607, United States
Saint Francis Hospital

Greenville, South Carolina, 29601, United States
Saint Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States
Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712, United States
Seattle Children's Hospital

Seattle, Washington, 98105, United States
Sinai Hospital of Baltimore

Baltimore, Maryland, 21215, United States
Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376, United States
Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141, United States
Siteman Cancer Center-South County

St Louis, Missouri, 63129, United States
Southeastern Medical Oncology Center-Clinton

Clinton, North Carolina, 28328, United States
Southeastern Medical Oncology Center-Goldsboro

Goldsboro, North Carolina, 27534, United States
Southeastern Medical Oncology Center-Jacksonville

Jacksonville, North Carolina, 28546, United States
State University of New York Upstate Medical University

Syracuse, New York, 13210, United States
Straub Clinic and Hospital

Honolulu, Hawaii, 96813, United States
Summerlin Hospital Medical Center

Las Vegas, Nevada, 89144, United States
Sunrise Hospital and Medical Center

Las Vegas, Nevada, 89109, United States
Texas Tech University Health Sciences Center-El Paso

El Paso, Texas, 79905, United States
The Carle Foundation Hospital

Urbana, Illinois, 61801, United States
The Children's Hospital at TriStar Centennial

Nashville, Tennessee, 37203, United States
The Steven and Alexandra Cohen Children's Medical Center of New York

New Hyde Park, New York, 11040, United States
UCSF Benioff Children's Hospital Oakland

Oakland, California, 94609, United States
UCSF Medical Center-Mission Bay

San Francisco, California, 94158, United States
UF Health Cancer Institute - Gainesville

Gainesville, Florida, 32610, United States
UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599, United States
UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637, United States
University of Illinois

Chicago, Illinois, 60612, United States
University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136, United States
University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, 55455, United States
University of Mississippi Medical Center

Jackson, Mississippi, 39216, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Vermont and State Agricultural College

Burlington, Vermont, 05405, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States
Valley Children's Hospital

Madera, California, 93636, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States
Wayne Memorial Hospital

Goldsboro, North Carolina, 27534, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Yale University

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.